227 related articles for article (PubMed ID: 7987985)
1. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
2. Comparative cytotoxicity of folate-based inhibitors of thymidylate synthase and 5-fluorouracil +/- leucovorin in MGH-U1 cells.
Erlichman C; Mitrovski B
Cancer Chemother Pharmacol; 1994; 34(1):51-6. PubMed ID: 8174202
[TBL] [Abstract][Full Text] [Related]
3. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
Pressacco J; Mitrovski B; Erlichman C; Hedley DW
Cancer Res; 1995 Apr; 55(7):1505-8. PubMed ID: 7882359
[TBL] [Abstract][Full Text] [Related]
4. Folate-based thymidylate synthase inhibitors as anticancer drugs.
Jackman AL; Calvert AH
Ann Oncol; 1995 Nov; 6(9):871-81. PubMed ID: 8624289
[TBL] [Abstract][Full Text] [Related]
5. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates.
Jackman AL; Marsham PR; Moran RG; Kimbell R; O'Connor BM; Hughes LR; Calvert AH
Adv Enzyme Regul; 1991; 31():13-27. PubMed ID: 1877386
[TBL] [Abstract][Full Text] [Related]
7. ICI D1694 and idoxuridine: a synergistic antitumor combination.
Pressacco J; Hedley DW; Erlichman C
Cancer Res; 1994 Jul; 54(14):3772-8. PubMed ID: 8033097
[TBL] [Abstract][Full Text] [Related]
8. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
Hanlon MH; Ferone R
Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
[TBL] [Abstract][Full Text] [Related]
9. Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Pressacco J; Erlichman C
Biochem Pharmacol; 1993 Dec; 46(11):1989-97. PubMed ID: 8267649
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase: a target for anticancer drug design.
Harrap KR; Jackman AL; Newell DR; Taylor GA; Hughes LR; Calvert AH
Adv Enzyme Regul; 1989; 29():161-79. PubMed ID: 2633608
[TBL] [Abstract][Full Text] [Related]
12. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
13. The complex of the anti-cancer therapeutic, BW1843U89, with thymidylate synthase at 2.0 A resolution: implications for a new mode of inhibition.
Stout TJ; Stroud RM
Structure; 1996 Jan; 4(1):67-77. PubMed ID: 8805515
[TBL] [Abstract][Full Text] [Related]
14. Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity.
Pressacco J; Mitrovski B; Hedley DW; Tsang R; Erlichman C
Biochem Pharmacol; 1995 Jun; 50(1):55-60. PubMed ID: 7605345
[TBL] [Abstract][Full Text] [Related]
15. Immunoreactive dUMP and TTP pools as an index of thymidylate synthase inhibition; effect of tomudex (ZD1694) and a nonpolyglutamated quinazoline antifolate (CB30900) in L1210 mouse leukaemia cells.
Aherne GW; Hardcastle A; Raynaud F; Jackman AL
Biochem Pharmacol; 1996 May; 51(10):1293-301. PubMed ID: 8787544
[TBL] [Abstract][Full Text] [Related]
16. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic and biochemical implications of combining AZT and AG-331.
Pressacco J; Mitrovski B; Erlichman C
Cancer Chemother Pharmacol; 1995; 35(5):387-90. PubMed ID: 7850919
[TBL] [Abstract][Full Text] [Related]
18. Binding of the anticancer drug ZD1694 to E. coli thymidylate synthase: assessing specificity and affinity.
Rutenber EE; Stroud RM
Structure; 1996 Nov; 4(11):1317-24. PubMed ID: 8939755
[TBL] [Abstract][Full Text] [Related]
19. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.
Chong LK; Tattersall MH
Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640
[TBL] [Abstract][Full Text] [Related]
20. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
